Clinuvel Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Clinuvel Pharmaceuticals ha aumentado sus beneficios a una tasa media anual de 14.4%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento de 12.8% anual. Los ingresos han ido creciendo a una tasa media de 23.9% al año. La rentabilidad financiera de Clinuvel Pharmaceuticals es de 16.9%, y sus márgenes netos son de 36.9%.

Información clave

14.4%

Tasa de crecimiento de los beneficios

13.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	9.6%
Tasa de crecimiento de los ingresos	23.9%
Rentabilidad financiera	16.9%
Margen neto	36.9%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Aug 11

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Nov 18

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Jul 30

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Feb 27

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

Dec 14

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

Nov 03

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Sep 23

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Jul 23

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Apr 10

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Mar 06

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Feb 27

What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Feb 20

Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Feb 01

Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jan 14

We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Dec 28

Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 10

What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Nov 21

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Clinuvel Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

ASX:CUV Ingresos, gastos y beneficios (AUD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	82	30	29	1
30 Sep 23	80	30	27	1
30 Jun 23	78	31	25	1
31 Mar 23	74	29	23	1
31 Dec 22	70	26	21	1
30 Sep 22	68	24	20	1
30 Jun 22	66	21	19	1
31 Mar 22	62	22	18	1
31 Dec 21	57	24	17	1
30 Sep 21	53	24	16	1
30 Jun 21	48	25	14	1
31 Mar 21	43	23	14	-1
31 Dec 20	38	21	14	-3
30 Sep 20	35	18	13	-1
30 Jun 20	33	15	12	0
31 Mar 20	32	15	10	4
31 Dec 19	32	15	8	8
30 Sep 19	32	16	7	7
30 Jun 19	31	18	6	7
31 Mar 19	29	17	6	7
31 Dec 18	27	16	6	6
30 Sep 18	26	15	6	6
30 Jun 18	25	13	6	6
31 Mar 18	21	10	6	5
31 Dec 17	17	6	6	5
30 Sep 17	17	7	6	4
30 Jun 17	17	7	5	4
31 Mar 17	14	5	5	4
31 Dec 16	12	3	4	4
30 Sep 16	9	0	4	4
30 Jun 16	7	-3	5	4
31 Mar 16	5	-5	3	3
31 Dec 15	4	-6	2	3
30 Sep 15	4	-8	4	3
30 Jun 15	3	-10	6	3
31 Mar 15	3	-10	8	3
31 Dec 14	3	-10	9	3
30 Sep 14	3	-8	7	3
30 Jun 14	3	-6	5	3
31 Mar 14	3	-6	5	3
31 Dec 13	2	-6	5	3
30 Sep 13	2	-6	5	4
30 Jun 13	2	-7	5	4

Ingresos de calidad: CUV tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(36.9%) de CUV son inferiores a los del año pasado (37.6%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de CUV han crecido un 14.4% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de CUV en el último año (14.2%) está por debajo de su media de 5 años (14.4% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de CUV en el último año (14.2%) superó al de la industria Biotechs -1%.

Clinuvel Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Información clave

Actualizaciones de resultados anteriores recientes

First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023)

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

First half 2023 earnings released: EPS: AU$0.23 (vs AU$0.12 in 1H 2022)

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Recent updates

Price target decreased by 7.4% to AU$25.01

First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023)

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Price target increased by 13% to AU$31.12

Price target decreased by 7.2% to AU$27.50

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Investor sentiment deteriorates as stock falls 20%

Now 22% undervalued

First half 2023 earnings released: EPS: AU$0.23 (vs AU$0.12 in 1H 2022)

Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant

Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation

Price target increased by 11% to AU$28.94

Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance

Clinuvel Pharmaceuticals Limited Shares the First Results of Phase II Study Evaluating Afamelanotide in Patients with Xeroderma Pigmentosum

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

No independent directors

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Clinuvel Pharmaceuticals Limited Announces Enrollment of First Patient in New Clinical Study CUV104

Investor sentiment improved over the past week

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022

Now 20% undervalued

Investor sentiment improved over the past week

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

CLINUVEL PHARMACEUTICALS LIMITED Intends to Evaluate its Drug Candidate PRÉNUMBRA Instant (Afamelanotide) as A Treatment for Patients Diagnosed with Arterial Ischaemic Stroke (AIS) in its Next Clinical Trial (CUV803)

Non-Executive Director recently sold AU$356k worth of stock

CLINUVEL Progresses CUV104 Vitiligo Study

CLINUVEL Releases Positive Final Results of the Open Label Pilot Study (CUV801) in Arterial Ischemic Stroke

No independent directors

Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director

Clinuvel Pharmaceuticals Limited Announces First XP-V Patient Treated in Third CUV DNA Repair Study

CEO, MD & Director recently sold AU$1.1m worth of stock

Now 22% undervalued after recent price drop

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to AU$27.32

Investor sentiment deteriorated over the past week

Clinuvel Pharmaceuticals Limited Completes Enrolment in CUV801 Stroke Study

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Full year 2021 earnings released: EPS AU$0.50 (vs AU$0.31 in FY 2020)

Investor sentiment improved over the past week

Price target increased to AU$33.92

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

CEO, MD & Director recently sold AU$3.7m worth of stock

Non-Executive Director recently sold AU$692k worth of stock

Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with Afamelanotide

CEO, MD & Director recently sold AU$3.1m worth of stock

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

CEO, MD & Director recently sold AU$2.6m worth of stock

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2021 Results on Aug 31, 2021

Investor sentiment improved over the past week

Analysts update estimates

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Revenue and earnings miss expectations

First half 2021 earnings released: EPS AU$0.13 (vs AU$0.013 in 1H 2020)

New 90-day low: AU$20.10

Clinuvel Pharmaceuticals Limited to Report First Half, 2021 Results on Feb 26, 2021

Desglose de ingresos y gastos
Beta